Dott. Giuseppe Auteri

14/03/2020 – ATTUALE RICERCATORE UNIVERSITARIO

Lavoro come Libero Professionista presso il reparto di Ematologia del Policlinico S. Orsola di Bologna, per conto del Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale.

31/10/2019 – 16/06/2023 Bologna, Italia DOTTORATO DI RICERCA ALMA MATER STUDIORUM

Dottorato di ricerca, ciclo XXXV, “Oncologia, Ematologia e Patologia”
Attività assistenziale (diagnostico-terapeutica) rivolta ai pazienti affetti da patologie ematologiche presso l’UO di Ematologia del Policlinico S. Orsola di Bologna, in maniera specifica ai pazienti affetti da Neoplasie Mieloproliferative croniche e Piastrinopenia Immune.

01/11/2015 – 30/10/2019 Bologna, Italia SPECIALIZZAZIONE IN EMATOLOGIA MINISTERO DELL’ISTRUZIONE, DELL’UNIVERSITÀ E DELLA RICERCA

31/07/2015 – 30/10/2015 Enna, Italia MEDICO DI CONTINUITÀ ASSISTENZIALE ASP ENNA

05/11/2019 Bologna, Italia SPECIALIZZAZIONE DI EMATOLOGIA Università di Bologna. Specializzazione in Ematologia FINAL EVALUATION: 110/110 + LODE – Livello EQF Livello 8 EQF

09/2014 – 05/2015 Belpasso (CT), Italia B1 CERTIFICATED ENGLISH COURSE WES

11/02/2015 Catania, Italia ABILITAZIONE ALLA PROFESSIONE MEDICA Università di Catania

12/10/2008 – 23/10/2014 Catania, Italia LAUREA IN MEDICINA E CHIRURGIA Università di Catania. FINAL EVALUATION: 110/110
Livello EQF Livello 7 EQF

08/09/2002 – 10/07/2007 Paternò, Italia MATURITÀ Liceo Socio-psicopedagogico F. De Sanctis, Paternò. FINAL EVALUATION: 100/100
Livello EQF Livello 4 EQF

• 2016 – New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment
• 2018 – Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34 + Cells
• 2018 – Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
• 2019 – Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients
• 2019 – Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis
• 2019 – Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
• 2018 – Differences in presenting features, outcome and prognostic models in patients with primary
  myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.
• 2019 – Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
• 2019 – Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
• 2019 – Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach
• 2020 – Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years
• 2020 – Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
• 2020 – Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
• Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms
• 2020 – The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
• 2020 – Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series
• 2021 – Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction
• 2021 – Second primary malignancy in myelofibrosis patients treated with ruxolitinib
• 2021 – Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
• 2021 – Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
• 2021 – Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
• 2021 – Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia
• 2021 – Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study
• 2021 – Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia
• 2021 – Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
• 2023 – Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
• 2023 – Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
• 2022 – Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
• 2022 – Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
• 2023 – Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study
• 2021 – The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report
• 2023 – Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
• 2021 – An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
• 2021 – An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
• 2021 – Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies
• 2021 – Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
• 2021 – A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera
• 2022 – Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study
• 2023 – Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study

– Regional Meeting about ITP. Splenectomy and Rituximab pros and cons. Bologna 27 Sep 2017
– Myeloproliferative Neoplasms Philadelphia negative. Focus on Polycythemia Vera. Diagnostic criteria.
Torino 23 Feb 2018
– Regional Meeting about Polycythemia Vera. Thromboses on PV and the role of ruxolitinib. Bologna 04 Jun
2018
– Regional Meeting about ITP. ITP in elderly patients. Bologna 26 Nov 2018.
– Scientific Meeting of the Seràgnoli Institute. Splanchnic Vein Thromboses and Myeloproliferative
Neoplasms. Bologna 24 Jan 2019.
– Meeting with patients with ITP. Why participate in clinical trials. Milano 16 Mar 2019
– Immune Thrombocytopenia: state of art and experience. ITP and surgery. Bologna 27 Jun 2019
– Regional meeting about PV. Resistance criteria to hydroxyurea. Bologna 08 Jul 2019
– Regional Meeting about ITP. About ITP patient and thrombosis. Bologna 18 Nov 2019
– Diagnosi differenziale delle piastrinosi. Lezione a specializzandi di Medicina Interna 2020-2021
– Trombosi Splancninche e Neoplasie Mieloproliferative Croniche. Lezione a specializzandi di Medicina
Interna 2020-2021
– Diagnosi differenziale delle piastrinopenie. Lezione a specializzandi di Medicina Interna 2020-2021
– Terapie di combinazione, pazienti refrattari e nuove terapie dell’ITP. Meeting regionale sull’ITP. Webinar.
18 Nov 2020
– Nuovi paradigmi terapeutici della Policitemia Vera. Meeting scientifici di Istituto. 09 Jan 2021
– COVID-19 e piastrinopenia. Riunione regionale ITP 06 Jun 2021
– Nuove Terapie Nella Trombocitemia Essenziale. Progetto Sabati Romagnoli 16 Oct 2021
– FAD regionale Sulla porpora trombotica trombocitopenica 23 Nov 2021
COMPETENZE PROFESSIONALI

CERTIFICAZIONI

ONORIFICENZE E RICONOSCIMENTI

PRESENTAZIONI

– Advanced ITP Discussion nazionale. Milano 20 Nov 2021
– Revolution on the Road. Discussione sull’ITP. Bologna 08-09 Apr 2022
– Meeting regionale. Gestione del paziente con ITP. Bologna 27 Apr 2022
– Meeting regionale sulla Mielofibrosi. Bologna 23 Sett 2022
– Policitemia Vera. Qualcosa è cambiato. Bologna 20 Feb 2023
– Up To Date sulle MPN e l’ITP. Early treatment nell’ITP. 04 Jul 2023
– Meeting internazionale sulle citopenie immuni. Practical pills in ITP. Rimini 09 Sep 2023
– Identikit del paziente candidato a terapia con fostamatinib. Bologna 22 Sep 2023
– In Their Present. Meeting multiregionale sull’ITP. 28 Sep 2023
– Meeting multiregionale sulla Mielofibrois. Gestione della seconda linea della mielofibrosi. 29 Sep 2023